Fructooligosaccharides (FOS) per Irritable Bowel Syndrome (IBS)
D Ricerca Esiste solo ricerca preliminare (studi di laboratorio, segnalazioni di casi).Mixed results. Low doses may help (5 g) but higher doses can worsen bloating due to rapid fermentation.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dfructooligosaccharides\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
D
In sintesi
Mixed results. Low doses may help (5 g) but higher doses can worsen bloating due to rapid fermentation.
Key Study Findings
Other
FODMAP Profile of Wholegrain Pasta.
Dose: None
vs: None
Outcome: FODMAP compound content in pasta (analytical)
Effetto: None
None
Popolazione: Commercially available pasta products (analytical study)
Randomized Controlled Trial
n=9
12 weeks
Modification of the Low FODMAP Diet Is Feasible in the Treatment of Irritable Bowel Syndrome: …
Dose: None
vs: Baseline; crossover between 3 diets
Outcome: Birmingham IBS questionnaire symptom score
Effetto: 75% relief on low FOS+GOS; 62.5% on FODMAP
p<0.05
Popolazione: IBS patients (Rome IV criteria)
Other
Biotechnological Tools for the Production of Low-FODMAP Wholegrain Wheat and Rye Cookies and Crackers.
Dose: None
vs: Standard wholegrain flour products
Outcome: FODMAP content reduction in cookies and crackers
Effetto: Up to 99.5% FODMAP reduction (wheat malt)
None
Popolazione: Laboratory food science study (no human subjects)
Randomized Controlled Trial
12 weeks
Double-blind
Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides …
Dose: None
vs: Placebo
Outcome: Quality of life
Effetto: None
p = 0.023
Popolazione: IBS patients
In Vitro
Microbial inulinase promotes fructan hydrolysis under simulated gastric conditions.
Dose: None
vs: None
Outcome: None
Effetto: None
None
Popolazione: None
Controlled Clinical Trial
n=54
3.0 weeks
[Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with …
Dose: 350 mg
vs: None
Outcome: IBS symptom improvement
Effetto: None
None
Popolazione: Irritable bowel syndrome with diarrhea and antibiotic-associated diarr
Key Statistics
2
Studi
150
Partecipanti
↔
Mixed
D
Grado
Referenced Papers
Foods (Basel, Switzerland)
2025
3 citazioni
Foods (Basel, Switzerland)
2025
1 citazioni
Gastroenterology research and …
2025
Journal of clinical …
2024
4 citazioni
Frontiers in nutrition
2023
8 citazioni
Voprosy pitaniia
2023
Carbohydrate polymers
2022
77 citazioni
FASEB journal : …
2022
16 citazioni
Journal of clinical …
2022
12 citazioni
Nutrients
2022
8 citazioni
Expert review of …
2022
8 citazioni
Food chemistry: X
2021
64 citazioni
Foods (Basel, Switzerland)
2021
10 citazioni
Nutrients
2020
78 citazioni
Journal of agricultural …
2018
13 citazioni
Neurogastroenterology and motility
2017
131 citazioni
Nutrition journal
2017
10 citazioni
Voprosy pitaniia
2013
The American journal …
2000
136 citazioni
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Dosaggi di uso comune
- general:
- 2-10 g/day
- prebioticeffect:
- 5-8 g/day for bifidogenic effect
- constipationsupport:
- 5-10 g/day
Limite massimo: Well-tolerated up to 20 g/day; start low to avoid excess gas
Dosaggi studiati nella ricerca
| Dosaggio | Durata | Effetto | N |
|---|---|---|---|
| None | -- | Neutral | -- |
| None | 12 weeks | Positive | 9 |
| None | -- | Positive | -- |
| None | 12 weeks | Positive | -- |
| None | -- | Mixed | -- |
| 350 mg | 3.0 weeks | Positive | 54 |
| None | -- | Mixed | -- |
| None | -- | Negative | -- |
Momento migliore per l'assunzione: With meals; divide doses throughout the day
Safety & Side Effects
Effetti collaterali segnalati
- ⚠ Gas, bloating, and flatulence (dose-dependent; more common above 10 g/day)
- ⚠ Abdominal cramping at higher doses
- ⚠ May worsen IBS symptoms in FODMAP-sensitive individuals
- ⚠ Loose stools at excessive doses
Interazioni note
- ● Other FODMAPs (cumulative fermentation effect in sensitive individuals)
- ● Blood sugar-lowering medications (FOS may modestly affect glycemic response)
- ● Calcium supplements (FOS may enhance calcium absorption)
Livello di assunzione massimo tollerabile: Well-tolerated up to 20 g/day; start low to avoid excess gas
Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.
Frequently Asked Questions
Does Fructooligosaccharides (FOS) help with Irritable Bowel Syndrome (IBS)?
Based on 2 studies with 150 participants, there is preliminary evidence that needs more research that Fructooligosaccharides (FOS) may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is D (Very Early Research).
How much Fructooligosaccharides (FOS) should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 2-10 g/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Fructooligosaccharides (FOS)?
Reported side effects may include Gas, bloating, and flatulence (dose-dependent; more common above 10 g/day), Abdominal cramping at higher doses, May worsen IBS symptoms in FODMAP-sensitive individuals, Loose stools at excessive doses. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Fructooligosaccharides (FOS) and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade D (Very Early Research). This rating is based on 2 peer-reviewed studies with 150 total participants. The overall direction of effect is mixed.
Related Evidence
Altri ingredienti per Irritable Bowel Syndrome (IBS)
Fructooligosaccharides (FOS) per altre condizioni
References
- [1] Aleksandra M Torbica et al.. Foods. 2025. FODMAP Profile of Wholegrain Pasta. doi:10.3390/foods14040667 PubMed
- [2] Aleksandra M Torbica et al.. Foods. 2025. Biotechnological Tools for the Production of Low-FODMAP Wholegrain Wheat and Rye Cookies and Crackers. doi:10.3390/foods14040582 PubMed
- [3] Line Graser Jensen et al.. Gastroenterol Res Pract. 2025. Modification of the Low FODMAP Diet Is Feasible in the Treatment of Irritable Bowel Syndrome: A Randomised Crossover Study. doi:10.1155/grp/4152978 PubMed
- [4] Anita Gąsiorowska et al.. J Clin Med. 2024. Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel … doi:10.3390/jcm14010006 PubMed
- [5] Justin L Guice et al.. Front Nutr. 2023. Microbial inulinase promotes fructan hydrolysis under simulated gastric conditions. doi:10.3389/fnut.2023.1129329 PubMed
- [6] V N Drozdov et al.. Vopr Pitan. 2023. [Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with irritable bowel syndrome with diarrhea … doi:10.33029/0042-8833-2023-92-4-92-103 PubMed
- [7] Ashinshana U Illippangama et al.. Carbohydr Polym. 2022. Inulin as a functional ingredient and their applications in meat products. doi:10.1016/j.carbpol.2021.118706 PubMed
- [8] J B J Kamphuis et al.. FASEB J. 2022. Increased fermentable carbohydrate intake alters colonic mucus barrier function through glycation processes and increased mast cell counts. doi:10.1096/fj.202100494RRR PubMed
- [9] Anita Gąsiorowska et al.. J Clin Med. 2022. Effects of Microencapsulated Sodium Butyrate, Probiotics and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome: A Study Protocol of … doi:10.3390/jcm11216587 PubMed
- [10] Susie Jung et al.. Nutrients. 2022. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Multi-Strain Synbiotic in Patients with Functional Diarrhea and High Fecal … doi:10.3390/nu14235017 PubMed
- [11] Diego Currò. Expert Rev Gastroenterol Hepatol. 2022. Current evidence on the therapeutic use of fiber in irritable bowel syndrome. doi:10.1080/17474124.2021.1924057 PubMed
- [12] Marcel Skejovic Joehnke et al.. Food Chem X. 2021. Nutritional and anti-nutritional properties of lentil (Lens culinaris) protein isolates prepared by pilot-scale processing. doi:10.1016/j.fochx.2020.100112 PubMed
- [13] Johannes Pitsch et al.. Foods. 2021. FODMAP Fingerprinting of Bakery Products and Sourdoughs: Quantitative Assessment and Content Reduction through Fermentation. doi:10.3390/foods10040894 PubMed
- [14] Barbara Skrzydło-Radomańska et al.. Nutrients. 2020. The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant … doi:10.3390/nu12071999 PubMed
- [15] Tobias Pöhnl et al.. J Agric Food Chem. 2018. Impact of Cultivation Method and Cultivar Selection on Soluble Carbohydrates and Pungent Principles in Onions ( Allium cepa L.). doi:10.1021/acs.jafc.8b05018 PubMed
- [16] F Azpiroz et al.. Neurogastroenterol Motil. 2017. Effects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable bowel syndrome: a randomized, double … doi:10.1111/nmo.12911 PubMed
- [17] Jennifer Erickson et al.. Nutr J. 2017. Gastrointestinal tolerance of low FODMAP oral nutrition supplements in healthy human subjects: a randomized controlled trial. doi:10.1186/s12937-017-0256-3 PubMed
- [18] V I Pilipenko et al.. Vopr Pitan. 2013. [Contemporary dietotherapy of the irritable bowel syndrome]. PubMed
- [19] M Olesen et al.. Am J Clin Nutr. 2000. Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. doi:10.1093/ajcn/72.6.1570 PubMed
Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.